Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix
Status:
Completed
Trial end date:
2017-05-09
Target enrollment:
Participant gender:
Summary
OBJECTIVE: The standard of care for high grade cervical intraepithelial neoplasia grade 2 to
3 (CIN 2-3) has been the excision of the cervical transformation zone by way of a loop
electrosurgical excision procedure (LEEP) or cold knife conization (CKC). However, it has
been recognized that these procedures can increase the risks for pre-term labor in women who
still desire to conceive. Recent studies have shown that medical treatment with Imiquimod, a
topical immune response modulator, has significant effects on histological regression of CIN
2-3 when compared with placebo. The investigators propose that treatment with Imiquimod may
be preferable offering similar outcomes on histological regression when compared with
excision or ablation while potentially avoiding or reducing the number of surgical procedure
that places them at risk for future pregnancies.